CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 52 enrolled
Drug / intervention
nicotine replacement therapy (nicotine patches) +1 moredrug
Likely dose
nicotine replacement therapy (nicotine patches) 21 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00939029
NCT00939029Phase 3Completed
CompareCT.gov

Highdose Nicotine Patch Therapy for Smokeless Tobacco Use

Mayo Clinic·interventional·Posted Jul 14, 2009·Updated May 19, 2014

In Brief

A Phase 3 clinical trial evaluating nicotine replacement therapy (nicotine patches) and placebo NRT for Smokeless Tobacco Use. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Smokeless tobacco use ("chewing") is associated with negative health effects. To date, no medications have been shown to help chewers quit long-term. High dose nicotine patch therapy may improve the chances that chewers can quit for good. If found to be effective, chewers may use this treatment to help them quit and reduce their risk for negative health effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmokeless Tobacco Use
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 14, 2009
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.0 years ago

Interventions

nicotine replacement therapy (nicotine patches)drug

2- 21 mg patches per day for 8 weeks

placebo NRTdrug

2 placebo patches (containing no active ingredient)per day for 8 weeks